Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma

BACKGROUND AIMS: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). However, CAR-T-related tumor lysis syndrome (TLS) has been observed. We aimed to elucidate the incidence, clinical and laboratory...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qiqi, Zu, Cheng, Jing, Ruirui, Feng, Youqin, Zhang, Yanlei, Zhang, Mingming, Lv, Yuqi, Cui, Jiazhen, Zhou, Linhui, Meng, Ye, Wang, Linqin, Cen, Zenan, Chang, Alex H., Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192732/
https://www.ncbi.nlm.nih.gov/pubmed/37215107
http://dx.doi.org/10.3389/fimmu.2023.1125357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192732/
https://www.ncbi.nlm.nih.gov/pubmed/37215107
http://dx.doi.org/10.3389/fimmu.2023.1125357

Ejemplares similares